Breaking News

Axplora Announces $41.2M Expansion at Farmabios Site

The addition of 62,000 square meters of new development in 2026 will more than double the total footprint of the site to 108,000 square meters.

Axplora has announced a transformative €35 million ($41.2 million) expansion at its Farmabios site in Gropello Cairoli, Italy.

This latest investment builds on the €45 million already committed over the past five years, bringing Axplora’s recent investment in Farmabios to over €80 million.

The addition of 62,000 square meters of new development in 2026 will more than double the total footprint of the site to 108,000 square meters. This will be more than ten times its original size in 1968.

“This expansion is not just a matter of scale, it’s about shaping the future of pharmaceutical manufacturing,” said Mario Di Giacomo, Managing Director of Farmabios. “We are investing with purpose: to enhance our capabilities, support our partners, and continue leading with innovation and integrity.”

About the Expansion

This expansion follows a period of accelerated growth at Farmabios. Key initiatives include the construction of a new micronisation department, expanded warehouse capacity, and the RS40 building – a state-of-the-art unit purpose-built for the safe and efficient handling of High Potent APIs (HPAPIs).

Designed in accordance with the most stringent safety and containment standards, RS40 employs a comprehensive exposure control strategy, including a layout based on exposure zoning that ensures strict segregation of high-potency operations within dedicated suites. The facility supports an Occupational Exposure Limit (OEL) as low as 10 nanograms per cubic meter and complies fully with OEB5 containment criteria. Its design incorporates stand-alone workshops and fully isolated process rooms to mitigate cross-contamination risks, offering maximum protection for both operators and products. In addition, the micronisation rooms are equipped with isolators specifically designed for HPAPI processing, ensuring safe handling of potent compounds at every stage.

“The Farmabios site reflects Axplora’s commitment to being a proactive, science-led, and sustainable partner,” said Martin Meeson, CEO of Axplora. “Every investment we make is guided by the ambition to deliver greater value to our customers, while raising the bar in reliability, speed and efficiency.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters